Haploidentical, Unmanipulated G-CSF-primed Peripheral Blood Stem Cell Transplantation for High-risk Hematologic Malignancies: an Update

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2016 Jun 21

PMID 27322853

Citations 9

Authors

W-R Huang

H-H Li

C-J Gao

J Bo

F Li

L-P Dou

L-L Wang

Y Jing

L Wang

D-H Liu

L Yu

Affiliations

Soon will be listed here.

Abstract

Emerging data demonstrate promising results of related haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HCT) for the treatment of hematologic malignancies. Data about G-CSF primed PBSC as reliable source of graft with myeloablative conditioning are lacking. We updated the outcomes in 130 adult patients with high-risk hematologic malignancies who received haplo-PBSC transplantation consecutively under busulfan-based conditioning. PBSC were freshly isolated and infused without ex vivo T-cell depletion into the recipients. Myeloid recovery was achieved in 99.2% patients with full donor chimerism. The cumulative incidence of acute grade 3-4 GvHD, overall and extensive chronic GvHD was 14.9%, 38.6% and 16.5%, respectively. The 3-year non-relapse mortality rate was 24.1%. Non-remission prior to transplant was associated with higher incidence of relapse (P=0.006), inferior overall survival (P=0.017) and leukemia-free survival (P=0.024). These data suggest that PBSC is a reliable graft source in haploidentical, unmanipulated transplant settings under myeloablative conditioning in patients with high-risk hematologic malignancies.

Citing Articles

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective....

Li X, Yang J, Cai Y, Huang C, Xu X, Qiu H Front Immunol. 2023; 14:1252879.

PMID: 37954615 PMC: 10639171. DOI: 10.3389/fimmu.2023.1252879.

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.

Huang Z, Yan H, Teng Y, Shi W, Xia L Front Immunol. 2022; 13:1017850.

PMID: 36458000 PMC: 9705727. DOI: 10.3389/fimmu.2022.1017850.

Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.

Chen T, Lin C, Lo W, Hsieh C, Lien M, Lin C Int J Hematol. 2022; 115(4):525-533.

PMID: 35226308 DOI: 10.1007/s12185-021-03280-x.

CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update.

Luo X, Zhu Y, Chen Y, Shui L, Liu L Front Immunol. 2021; 12:732826.

PMID: 34777342 PMC: 8580860. DOI: 10.3389/fimmu.2021.732826.

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas.

Zhenyang G, Nainong L, Xiaoxiong W, Maihong W, Xiaorui F, Zhao W Cell Transplant. 2021; 30:963689721999615.

PMID: 33745341 PMC: 7989122. DOI: 10.1177/0963689721999615.

References

Lu D, Dong L, Wu T, Huang X, Zhang M, Han W . Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2005; 107(8):3065-73. DOI: 10.1182/blood-2005-05-2146. View

Anasetti C, Logan B, Lee S, Waller E, Weisdorf D, Wingard J . Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367(16):1487-96. PMC: 3816375. DOI: 10.1056/NEJMoa1203517. View

Friedrichs B, Tichelli A, Bacigalupo A, Russell N, Ruutu T, Shapira M . Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol. 2010; 11(4):331-8. DOI: 10.1016/S1470-2045(09)70352-3. View

Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B . Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2014; 20(5):724-9. DOI: 10.1016/j.bbmt.2014.02.001. View

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M . Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014; 20(6):890-5. PMC: 4451937. DOI: 10.1016/j.bbmt.2014.03.003. View

Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J . Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000; 355(9211):1231-7. DOI: 10.1016/S0140-6736(00)02090-0. View

Huang W, Li H, Gao C, Bo J, Wang Q, Zhao Y . Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion. 2012; 52(6):1354-62. DOI: 10.1111/j.1537-2995.2011.03478.x. View

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S . Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005; 23(15):3447-54. DOI: 10.1200/JCO.2005.09.117. View

Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J . T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014; 124(17):2735-43. PMC: 4208287. DOI: 10.1182/blood-2014-04-571570. View

10.

Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen D, Stuhler G . Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012; 97(10):1523-31. PMC: 3487553. DOI: 10.3324/haematol.2011.059378. View

11.

Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R . Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2012; 121(5):849-57. DOI: 10.1182/blood-2012-08-453399. View

12.

Schmitz N, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E . Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica. 2005; 90(5):643-8. View

13.

Kong Y, Hu Y, Zhang X, Wang Y, Mo X, Zhang Y . Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(8):1190-7. DOI: 10.1016/j.bbmt.2014.04.015. View

14.

Wang Y, Liu D, Liu K, Xu L, Zhang X, Han W . Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2012; 119(5):978-85. DOI: 10.1002/cncr.27761. View

15.

Wang Y, Chang Y, Xu L, Liu K, Liu D, Zhang X . Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood. 2014; 124(6):843-50. DOI: 10.1182/blood-2014-03-563130. View

16.

Luznik L, ODonnell P, Symons H, Chen A, Leffell M, Zahurak M . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50. PMC: 2633246. DOI: 10.1016/j.bbmt.2008.03.005. View

17.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland H . Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free.... Biol Blood Marrow Transplant. 2012; 18(12):1859-66. DOI: 10.1016/j.bbmt.2012.06.019. View

18.

Xu L, Liu K, Liu D, Chen H, Han W, Chen Y . The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant. 2009; 45(6):985-92. DOI: 10.1038/bmt.2009.311. View

19.

Rowlings P, Przepiorka D, Klein J, Gale R, Passweg J, Henslee-Downey P . IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97(4):855-64. DOI: 10.1046/j.1365-2141.1997.1112925.x. View

20.

Chang Y, Xu L, Liu D, Liu K, Han W, Chen Y . Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant. 2009; 15(5):632-8. DOI: 10.1016/j.bbmt.2009.02.001. View